145 related articles for article (PubMed ID: 20665889)
1. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
Mihu CN; Kassis C; Ramos ER; Jiang Y; Hachem RY; Raad II
Cancer; 2010 Nov; 116(22):5290-6. PubMed ID: 20665889
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
3. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
Caillot D; Thiébaut A; Herbrecht R; de Botton S; Pigneux A; Bernard F; Larché J; Monchecourt F; Alfandari S; Mahi L
Cancer; 2007 Dec; 110(12):2740-6. PubMed ID: 17941026
[TBL] [Abstract][Full Text] [Related]
6. Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial.
Lass-Flörl C
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):929-32. PubMed ID: 18039077
[TBL] [Abstract][Full Text] [Related]
7. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
Lionakis MS; Lewis RE; Chamilos G; Kontoyiannis DP
Pharmacotherapy; 2005 Sep; 25(9):1174-80. PubMed ID: 16164392
[TBL] [Abstract][Full Text] [Related]
8. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
[TBL] [Abstract][Full Text] [Related]
9. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
Steinbach WJ; Stevens DA; Denning DW
Clin Infect Dis; 2003 Oct; 37 Suppl 3():S188-224. PubMed ID: 12975752
[TBL] [Abstract][Full Text] [Related]
10. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
11. [Progress in combination therapy for invasive aspergillosis].
Luo L; Tong Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973
[No Abstract] [Full Text] [Related]
12. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.
Kirkpatrick WR; Vallor AC; McAtee RK; Ryder NS; Fothergill AW; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2005 Nov; 49(11):4751-3. PubMed ID: 16251321
[TBL] [Abstract][Full Text] [Related]
13. [Invasive Aspergillosis in Hematological Patients].
Kimura S
Med Mycol J; 2016; 57(2):J77-88. PubMed ID: 27251320
[TBL] [Abstract][Full Text] [Related]
14. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
[TBL] [Abstract][Full Text] [Related]
17. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
20. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
